Next Article in Journal
C-MYC Inhibited Ferroptosis and Promoted Immune Evasion in Ovarian Cancer Cells through NCOA4 Mediated Ferritin Autophagy
Previous Article in Journal
QTLs Related to Rice Callus Regeneration Ability: Localization and Effect Verification of qPRR3
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 11
Issue 24
10.3390/cells11244126
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cells 2022, 11(13), 2107.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107

by
Harinder Gill
Department of Medicine, LKS Faculty of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China
Cells 2022, 11(24), 4126; https://doi.org/10.3390/cells11244126
Submission received: 26 September 2022 / Accepted: 30 September 2022 / Published: 19 December 2022
Versions Notes

Text Correction

The authors would like to make the following corrections to the published paper [1]:
The acknowledgments are missing. Bomedemstat, the most successful LSD1 inhibitor, was developed by Dr. Hugh Y Rienhoff and his team at Imago Biosciences, and many ideas in this review were inspired by Dr. Rienhoff and his story. Therefore, the author feels a strong need to acknowledge them in a correction notice. The corrected acknowledgments should read as follows:
Acknowledgments: The author would like to acknowledge Hugh Young Rienhoff and his team at Imago Biosciences for their work on the role of LSD1 and the development of IMG-7289 (Bomedemstat), which inspired this manuscript.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Gill, H. Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107. Cells 2022, 11, 4126. https://doi.org/10.3390/cells11244126

AMA Style

Gill H. Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107. Cells. 2022; 11(24):4126. https://doi.org/10.3390/cells11244126

Chicago/Turabian Style

Gill, Harinder. 2022. "Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107" Cells 11, no. 24: 4126. https://doi.org/10.3390/cells11244126

APA Style

Gill, H. (2022). Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107. Cells, 11(24), 4126. https://doi.org/10.3390/cells11244126

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop